Form 4: Editas Medicine EVP Linda Burkly Sells Shares to Cover Tax Obligations

EVP and Chief Scientific Officer of Editas Medicine, Linda Burkly, sold 2,891 shares of common stock on March 4, 2025, to cover tax obligations resulting from vesting restricted stock units.

Summary

• Linda Burkly, EVP and Chief Scientific Officer of Editas Medicine, sold 2,891 shares of common stock on March 4, 2025.
• The sale was executed at a price of $1.7107 per share.
• The transaction was conducted to meet tax withholding obligations related to the vesting of restricted stock units on March 2, 2025.
• Following the transaction, Burkly directly owns 70,245 shares of Editas Medicine.
• The sale was executed under a pre-arranged automatic sales instruction plan adopted on July 3, 2023.
• A Limited Power of Attorney was executed on March 5, 2025, appointing Erick Lucera, Damien Grierson, and Amy Parison as attorneys-in-fact for Section 16 reporting obligations.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to tax obligations and doesn't indicate a significant positive or negative outlook for the company.

Positives

• The sale was executed under a pre-arranged automatic sales instruction plan, indicating it was not a discretionary trade based on current market conditions.

Future Outlook

There is no future outlook provided in this document.

Management Comments

• The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

This is a routine transaction related to executive compensation and tax obligations, common in publicly traded companies. It doesn't necessarily reflect a change in the executive's confidence in the company.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Companies like CRISPR Therapeutics and Intellia Therapeutics also see similar transactions from their executives.
• These sales are typically pre-planned and do not necessarily indicate a negative outlook on the company's future performance.

Stakeholder Impact

• The sale of shares by an executive could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.

Key Dates